1/5 BREAKING NEWS: Novartis pays $2B upfront to acquire Synnovation Therapeutics's pan-mutant-selective PI3Kα inhibitor program — a strategic bet to defend its breast cancer franchise. 🧵
1
0
0
209
4/5 The lead asset: SNV4818 — a pan-mutant-selective PI3Kα inhibitor in Phase 1/2 in breast cancer and solid tumors.
Being tested as:
â–¸ Monotherapy
â–¸ + Faslodex
â–¸ + Ibrance
Being tested as:
â–¸ Monotherapy
â–¸ + Faslodex
â–¸ + Ibrance
1
0
0
132
5/5 Deal expected to close mid-2026.
$2B upfront for a Phase 1/2 asset signals how much Novartis values next-gen selectivity — and how competitive the PI3Kα space is becoming.
$2B upfront for a Phase 1/2 asset signals how much Novartis values next-gen selectivity — and how competitive the PI3Kα space is becoming.
0
0
0
91
1/7 These drugs generated the highest sales in 2025 — and 2025 marked a genuine shift in who holds the power. 🧵
1
0
2
213
6/7 Blockbusters still dominate — but the map is being redrawn. Onco-immunology built the last decade. GLP-1s may define the next one.
1
0
0
82
7/7 Drop your thoughts below 👇
— Dr Jojo | Follow for pharma & biotech industry news. Share if this was useful.
— Dr Jojo | Follow for pharma & biotech industry news. Share if this was useful.
0
0
0
77
1/6 BIG NEWS: Johnson & Johnson reports an 89% complete response rate with intravesical targeted therapy in early-stage bladder cancer 🧵
1
0
0
118
5/6 Phase 1 results:
✅ 89% complete response rate (intermediate-risk)
✅ 83% recurrence-free at 12 months (high-risk)
✅ Median duration of complete response: 18 months
✅ 89% complete response rate (intermediate-risk)
✅ 83% recurrence-free at 12 months (high-risk)
✅ Median duration of complete response: 18 months
1
0
0
59
6/6 Erda-iDRS would be the first precision-based, biology-driven treatment for early-stage bladder cancer. Phase 3 studies (MoonRISe-1 & MoonRISe-3) are ongoing.
0
0
0
54
Which drugs drove the most revenue for pharma giants in 2025?
I mapped the top 3 selling medicines across 12 major companies - from $41B to $65B in revenue.
Here's what the data tells us 🧵
I mapped the top 3 selling medicines across 12 major companies - from $41B to $65B in revenue.
Here's what the data tells us 🧵
1
2
5
470
@abbvie deserves a mention.
Skyrizi and Rinvoq have more than absorbed the Humira biosimilar erosion - a transition many analysts flagged as an existential risk just a few years ago.
That's pipeline execution done right.
Skyrizi and Rinvoq have more than absorbed the Humira biosimilar erosion - a transition many analysts flagged as an existential risk just a few years ago.
That's pipeline execution done right.
1
0
0
118